530 related articles for article (PubMed ID: 26746091)
1. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
[TBL] [Abstract][Full Text] [Related]
2. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.
Kahler-Ribeiro-Fontana S; Pagan E; Magnoni F; Vicini E; Morigi C; Corso G; Intra M; Canegallo F; Ratini S; Leonardi MC; La Rocca E; Bagnardi V; Montagna E; Colleoni M; Viale G; Bottiglieri L; Grana CM; Biasuz JV; Veronesi P; Galimberti V
Eur J Surg Oncol; 2021 Apr; 47(4):804-812. PubMed ID: 33092968
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
[TBL] [Abstract][Full Text] [Related]
4. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node biopsy after neoadjuvant treatment in breast cancer: Work in progress.
Rubio IT
Eur J Surg Oncol; 2016 Mar; 42(3):326-32. PubMed ID: 26774943
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
[TBL] [Abstract][Full Text] [Related]
7. "Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients".
van Wely BJ; van den Wildenberg FJ; Gobardhan P; van Dalen T; Borel Rinkes IH; Theunissen EB; Wijsman JH; Ernst M; van der Pol CC; Madsen EV; Vles WJ; Wauters CA; de Wilt JH; Strobbe LJ
Eur J Surg Oncol; 2012 Oct; 38(10):925-31. PubMed ID: 22633152
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
[TBL] [Abstract][Full Text] [Related]
9. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
10. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
11. Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up.
Ogawa Y; Ikeda K; Watanabe C; Kamei Y; Tokunaga S; Tsuboguchi Y; Inoue T; Fukushima H; Ichiki M
Surg Today; 2018 Jan; 48(1):87-94. PubMed ID: 28647776
[TBL] [Abstract][Full Text] [Related]
12. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
14. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients.
Martelli G; Boracchi P; Orenti A; Lozza L; Maugeri I; Vetrella G; Agresti R
Eur J Surg Oncol; 2014 Jul; 40(7):805-12. PubMed ID: 24768443
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease.
Galimberti V; Manika A; Maisonneuve P; Corso G; Salazar Moltrasio L; Intra M; Gentilini O; Veronesi P; Pagani G; Rossi E; Bottiglieri L; Viale G; Rotmensz N; De Cicco C; Grana CM; Sangalli C; Luini A
Eur J Surg Oncol; 2014 Oct; 40(10):1203-8. PubMed ID: 25186914
[TBL] [Abstract][Full Text] [Related]
16. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study.
Martelli G; Miceli R; Folli S; Guzzetti E; Chifu C; Maugeri I; Ferranti C; Bianchi G; Capri G; Carcangiu ML; Paolini B; Agresti R; Ferraris C; Piromalli D; Greco M
Eur J Surg Oncol; 2017 Nov; 43(11):2012-2020. PubMed ID: 28912071
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Basik M; Florianova L; Margolese R; Dumitra S; Muanza T; Carbonneau A; Ferrario C; Boileau JF
Ann Surg Oncol; 2021 May; 28(5):2621-2629. PubMed ID: 33095362
[TBL] [Abstract][Full Text] [Related]
18. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
19. Positive axillary sentinel lymph node: is axillary dissection always necessary?
Galimberti V; Chifu C; Rodriguez Perez S; Veronesi P; Intra M; Botteri E; Mastropasqua M; Colleoni M; Luini A; Veronesi U
Breast; 2011 Oct; 20 Suppl 3():S96-8. PubMed ID: 22015302
[TBL] [Abstract][Full Text] [Related]
20. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.
Jones JL; Zabicki K; Christian RL; Gadd MA; Hughes KS; Lesnikoski BA; Rhei E; Specht MC; Dominguez FJ; Smith BL
Am J Surg; 2005 Oct; 190(4):517-20. PubMed ID: 16164912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
